iNCOVACC COVID-19 vaccine: A Twitter based Social Media Analysis Using Natural Language Processing, Sentiment Analysis, and Topic Modelling

Q4 Veterinary
Praveen Sv, Pooja Upasana Bhanj, Paras Jha, Deepak Chandran, Prachi Singh, Sandip Chakraborty, Abhijit Dey, K. Dhama
{"title":"iNCOVACC COVID-19 vaccine: A Twitter based Social Media Analysis Using Natural Language Processing, Sentiment Analysis, and Topic Modelling","authors":"Praveen Sv, Pooja Upasana Bhanj, Paras Jha, Deepak Chandran, Prachi Singh, Sandip Chakraborty, Abhijit Dey, K. Dhama","doi":"10.18006/2023.11(1).150.157","DOIUrl":null,"url":null,"abstract":"Most, if not all, the vaccine candidates designed to counteract COVID-19 due to SARS-CoV-2 infection require parenteral administration. Mucosal immunity established by vaccination could significantly contribute to containing the SARS-CoV-2 pandemic, which is spread by infected respiratory secretions. The world has been impacted on many fronts by the COVID-19 pandemic since early 2020 and has yet to recover entirely from the impact of the crisis. In late 2022 and early 2023, China experienced a new surge of COVID-19 outbreaks, mainly in the country's northeastern region. With the threat of new variants like XBB 1.5 and BF.7, India might experience a similar COVID-19 surge as China and needs to be prepared to avoid destruction again. An intranasal vaccine can elicit multiple immunological responses, including IgG neutralization, mucosal IgA production, and T-cell responses. In order to prevent further infection and the spread of COVID-19, local immune responses in the nasal mucosa are required. iNCOVACC is a recombinant vaccine vectored by an adenovirus that contains a SARS-CoV-2 spike protein that has been pre-fusion stabilized. This vaccine candidate has shown promise in both early and late-stage clinical trials. iNCOVACC has been designed for intranasal administration via nasal drops. The nasal delivery system was created to reduce expenses for those living in poor and moderate-income countries. The newly introduced intranasal COVID vaccine will be beneficial in mass immunizing the public as it does not need any syringe and can be proven to be an effective method to boost immunity against the SARS-CoV-2 virus. This study uses natural language processing (NLP) techniques to analyze the Indian citizen's perceptions of the newly developed iNCOVACC vaccine in social media. For this study, we have used social media posts (tweets) as data. We have analyzed 125,300 tweets to study the general perception of Indian citizens regarding the iNCOVACC vaccine. Our results have indicated 43.19% of social media posts discussing the COVID-19 nasal vaccine in a neutral tone, nearly 34.29% of social media posts are positive, and 22.5% of social media posts discussions are negative. The general positive feeling that the iNCOVACC vaccine will work and the risks in the new vaccine are the two significant aspects Indian citizens voice out in social media posts about the iNCOVACC vaccine.","PeriodicalId":15766,"journal":{"name":"Journal of Experimental Biology and Agricultural Sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental Biology and Agricultural Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18006/2023.11(1).150.157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Veterinary","Score":null,"Total":0}
引用次数: 0

Abstract

Most, if not all, the vaccine candidates designed to counteract COVID-19 due to SARS-CoV-2 infection require parenteral administration. Mucosal immunity established by vaccination could significantly contribute to containing the SARS-CoV-2 pandemic, which is spread by infected respiratory secretions. The world has been impacted on many fronts by the COVID-19 pandemic since early 2020 and has yet to recover entirely from the impact of the crisis. In late 2022 and early 2023, China experienced a new surge of COVID-19 outbreaks, mainly in the country's northeastern region. With the threat of new variants like XBB 1.5 and BF.7, India might experience a similar COVID-19 surge as China and needs to be prepared to avoid destruction again. An intranasal vaccine can elicit multiple immunological responses, including IgG neutralization, mucosal IgA production, and T-cell responses. In order to prevent further infection and the spread of COVID-19, local immune responses in the nasal mucosa are required. iNCOVACC is a recombinant vaccine vectored by an adenovirus that contains a SARS-CoV-2 spike protein that has been pre-fusion stabilized. This vaccine candidate has shown promise in both early and late-stage clinical trials. iNCOVACC has been designed for intranasal administration via nasal drops. The nasal delivery system was created to reduce expenses for those living in poor and moderate-income countries. The newly introduced intranasal COVID vaccine will be beneficial in mass immunizing the public as it does not need any syringe and can be proven to be an effective method to boost immunity against the SARS-CoV-2 virus. This study uses natural language processing (NLP) techniques to analyze the Indian citizen's perceptions of the newly developed iNCOVACC vaccine in social media. For this study, we have used social media posts (tweets) as data. We have analyzed 125,300 tweets to study the general perception of Indian citizens regarding the iNCOVACC vaccine. Our results have indicated 43.19% of social media posts discussing the COVID-19 nasal vaccine in a neutral tone, nearly 34.29% of social media posts are positive, and 22.5% of social media posts discussions are negative. The general positive feeling that the iNCOVACC vaccine will work and the risks in the new vaccine are the two significant aspects Indian citizens voice out in social media posts about the iNCOVACC vaccine.
iNCOVACC COVID-19疫苗:使用自然语言处理、情感分析和主题建模的基于Twitter的社交媒体分析
大多数(如果不是全部)设计用于对抗因SARS-CoV-2感染而导致的COVID-19的候选疫苗需要肠外注射。通过疫苗接种建立的粘膜免疫可以显著有助于遏制SARS-CoV-2大流行,SARS-CoV-2是通过受感染的呼吸道分泌物传播的。自2020年初以来,世界在许多方面受到COVID-19大流行的影响,尚未完全从危机的影响中恢复过来。在2022年底和2023年初,中国经历了新一波COVID-19疫情,主要发生在中国东北地区。随着XBB 1.5和BF.7等新变种的威胁,印度可能会经历与中国类似的COVID-19激增,需要准备好避免再次遭受破坏。鼻内疫苗可引起多种免疫反应,包括IgG中和、粘膜IgA产生和t细胞反应。为了防止COVID-19的进一步感染和传播,需要鼻黏膜的局部免疫反应。iNCOVACC是一种重组疫苗,载体是一种腺病毒,其中含有已预融合稳定的SARS-CoV-2刺突蛋白。这种候选疫苗在早期和后期临床试验中都显示出希望。iNCOVACC被设计为通过滴鼻给药。鼻给药系统的创建是为了减少生活在贫穷和中等收入国家的人们的费用。新推出的“鼻内疫苗”不需要注射器,而且可以有效提高对SARS-CoV-2病毒的免疫力,因此对大众免疫有很大帮助。本研究使用自然语言处理(NLP)技术分析印度公民在社交媒体上对新开发的iNCOVACC疫苗的看法。在本研究中,我们使用社交媒体帖子(tweets)作为数据。我们分析了125,300条推文,以研究印度公民对iNCOVACC疫苗的总体看法。我们的研究结果显示,43.19%的社交媒体帖子以中性语气讨论新冠病毒鼻用疫苗,近34.29%的社交媒体帖子为正面,22.5%的社交媒体帖子为负面。印度公民在社交媒体上就iNCOVACC疫苗发表的两个重要观点是,人们普遍认为iNCOVACC疫苗将起作用,以及新疫苗存在的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Experimental Biology and Agricultural Sciences
Journal of Experimental Biology and Agricultural Sciences Agricultural and Biological Sciences-Agricultural and Biological Sciences (all)
CiteScore
1.00
自引率
0.00%
发文量
127
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信